Protalix BioTherapeutics, Inc. PLX
2.72
(0.03)
(1.09%)
as of 25 Sep
- Market cap
- $221.6M
- P/E
- 11.3×
Follow PLX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
12.64% | (14.44%) | 27.27% | 31.23% | |
| 7.50% | (8.48%) | 17.40% | 20.07% | ||
ROIC |
16.91% | (19.92%) | 80.14% | 48.48% | |
Return on Tangible Assets |
10.95% | (14.66%) | 23.91% | 28.58% | |
Average Days of Receivables |
85.14 | 61.17 | 14.04 | 74.72 | |
Free Cash Flow per Share |
(0.15) | (0.17) | 0.16 | 0.10 | |
Free Cash Flow |
(11.69) | (13.63) | 13.00 | 7.67 | |
Capital Expenditures |
(1.66) | (1.64) | (2.09) | (2.25) | |
Piotroski F-Score |
5.00 | 2.00 | 6.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
(12.19%) | (15.14%) | 12.68% | 8.80% | |
Accounts Receivable Turnover |
7.44 | 8.98 | 16.60 | 6.21 | |
Accounts Payable Turnover |
1.21 | 1.10 | 0.94 | 0.95 | |
Inventory Turnover |
1.37 | 1.15 | 0.92 | 0.93 | |
Average Days of Payables |
285.61 | 339.86 | 412.97 | 436.92 | |
Days of Inventory on Hand |
295.43 | 347.91 | 484.87 | 474.65 | |
Tax Rate |
(0.17) | 0.18 | (0.20) | (0.19) | |
Research and Development Expense of Revenue |
29.20% | 37.10% | 28.17% | 24.66% | |
Selling, General and Administrative Expense of Revenue |
18.04% | 22.15% | 15.88% | 15.65% | |
Share Based Compensation of Revenue |
3.59% | 4.35% | 3.00% | 2.80% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(1.86) | 1.82 | 0.98 | 0.52 | |
Depreciation/Fixed assets |
0.30 | 0.30 | 0.30 | 0.29 | |
Capex/Depreciation |
(1.18) | (1.12) | (1.37) | (1.44) | |
Revenue per Share |
0.78 | 0.67 | 0.96 | 1.01 | |
Operating CF per Share |
(0.13) | (0.15) | 0.19 | 0.12 | |
Capex per Share |
(0.02) | (0.02) | (0.03) | (0.03) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 | |
Net Profit Margin |
8.72% | (12.52%) | 20.07% | 23.50% |
Columns are period end dates